Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RRG001 in Proliferative Diabetic Retinopathy
NCT06412224Phase 1Recruiting
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RRG001 in proliferative diabetic retinopathy (PDR). Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 24 weeks. Started Dec 2023; status: recruiting.
02
Drugs
RRG001
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT06412224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412224.